HIV-1 is capable of mimicking the ligand of integrin α4β7 by displaying a tripeptide mimotope on the V2 region. Through this mimicry HIV can bind the α4β7 integrin and get carried through the lymphocyte proliferation signaling pathway, cell-to-cell adhesion and can migrate to gut-associated lymphoid tissues. The same tripeptide motif was suggested to be the epicenter of neutralization in laboratory strains of HIV-1. In this study, we compared the α4β7 binding sites of two HIV-1 subtypes prevalent in China and found that the tripeptide binding domain of α4β7 was more diverse in subtype B’ strains than in CRF07_BC.
WagnerN, LohlerJ, KunkelEJet al.Critical role for β7 integrins in formation of the gut-associated lymphoid tissue. Nature, 1996; 382:366–370.
3.
ArthosJ, CicalaC, MartinelliEet al.HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol, 2008; 9:301–309.
4.
CicalaC, MartinelliE, McNallyJPet al.The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA, 2009; 106:20877–20882.
RongR, GnanakaranS, DeckerJMet al.Unique mutational patterns in the envelope α2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol, 2007; 81:5658–5668.
7.
HaaseAT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol, 2005; 5:783–792.
8.
MehandruS, PolesMA, Tenner-RaczKet al.Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol, 2007; 81:599–612.
9.
XuJQ, WangJJ, HanLFet al.Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. Chin Med J (Engl), 2006; 119:1941–1948.
10.
LiuS, XingH, HeXet al.Analysis of putative N-linked glycosylation sites and variable region of envelope HIV-1 CRF07_BC recombinant in intravenous drug users in Xinjiang Autonomous Region, China. AIDS Res Hum Retroviruses, 2008; 24:521–527.
11.
ZhouXL, HeX, HongKXet al.[Genetic variation of gag gene in HIV-1 subtype B infections from Henan and Shanxi provinces of China]Bing Du Xue Bao, 2009; 25:95–100.
12.
RuanY, QinG, LiuSet al.HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J Acquir Immune Defic Syndr, 2005; 39:459–463.
13.
ShaoY, ZhaoF, YangW. [The identification of recombinant HIV-1 strains in IDUs in southwest and northwest China]Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 1999; 13:109–112.
14.
LiY, ClevelandB, KlotsIet al.Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol, 2008; 82:638–651.
15.
ShannonCE. A mathematical theory of communication. Bell System Technical J, 1948; 27:379–423and 623–656.
16.
O'RourkeSM, SchweighardtB, PhungPet al.Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol, 2010; 84:11200–11209.
17.
GaschenB, KuikenC, KorberB, FoleyB. Retrieval and on-the-fly alignment of sequence fragments from the HIV database. Bioinformatics, 2001; 17:415–418.
18.
CaoJ, SullivanN, DesjardinEet al.Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol, 1997; 71:9808–9812.
19.
Cheng-MayerC, BrownA, HarouseJ, LuciwPA, MayerAJ. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol, 1999; 73:5294–5300.
20.
JohnsonWE, SanfordH, SchwallLet al.Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol, 2003; 77:9993–10003.
21.
YeY, SiZH, MooreJP, SodroskiJ. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo. J Virol, 2000; 74:11955–11962.
22.
AshkenaziA, SmithDH, MarstersSAet al.Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc Natl Acad Sci USA, 1991; 88:7056–7060.
23.
KochM, PanceraM, KwongPDet al.Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology, 2003; 313:387–400.
24.
KwongPD, WyattR, MajeedSet al.Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure, 2000; 8:1329–1339.
25.
SeamanMS, JanesH, HawkinsNet al.Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol, 2010; 84:1439–1452.
26.
MoorePL, RanchobeN, LambsonBEet al.Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog, 2009; 5:e1000598.
27.
RongR, LiB, LynchRMet al.Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog, 2009; 5:e1000594.
28.
WeiX, DeckerJM, WangSet al.Antibody neutralization and escape by HIV-1. Nature, 2003; 422:307–312.
